
	<p>N-(3-((2-((2-(piperidin-1-ylmethyl)quinolin-6-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide</p>
---	--

and pharmaceutically acceptable salts thereof.

21. The compound of claim 1, wherein the compound is a compound of Formula (VII):



wherein

R^1 and R^2 are independently selected from hydrogen, halo, C_{1-6} alkyl, and C_{1-6} haloalkyl;

R^8 is selected from halo, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, hydroxyl, cyano, and nitro;

R^{10} is C_{1-6} alkyl; and

R^{13} is hydrogen or C_{1-6} alkyl;

or a pharmaceutically acceptable salt thereof.

22. A pharmaceutical composition comprising (a) at least one compound of any of claims 1-21 or a pharmaceutically acceptable salt thereof, and (b) a pharmaceutically acceptable carrier or excipient.

23. The compound of any of claims 1-21 or a pharmaceutically acceptable salt thereof, for use in a method of treating and/or preventing a proliferation disorder, cancer, a

tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease, ~~comprising wherein said compound or pharmaceutically acceptable salt thereof is for administering in an effective amount to a subject in need of such treatment in an effective amount of at least one compound of any of claims 1-21 or a pharmaceutically acceptable salt thereof.~~

24. The compound or a pharmaceutically acceptable salt thereof, for the use ~~method~~ of claim 23, wherein the proliferation disorder is selected from the group consisting of sarcoma, epidermoid cancer, fibrosarcoma, cervical cancer, gastric carcinoma, skin cancer, leukemia, lymphoma, lung cancer, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, breast cancer, liver cancer, head and neck cancers, and pancreatic cancer.

25. The compound or a pharmaceutically acceptable salt thereof, ~~method~~ for the use of claim 23, wherein said compound is for further comprising administering in an effective amount of a second prophylactic or therapeutic agent for use in treating and/or preventing a proliferation disorder in a subject.

26. The compound N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide or a pharmaceutically acceptable salt thereof.

27. The compound of claim 26, wherein the compound is N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide hydrochloride salt or maleate salt.

28. The pharmaceutical composition of claim 22, wherein the pharmaceutically acceptable salt is a HCl salt, a maleate salt, a HBr salt, a hydroxybutanedioic acid salt or a fumaric acid salt.

29. ~~The method~~ compound for the use of claim 23, wherein the pharmaceutically acceptable salt is a HCl salt, a maleate salt, a HBr salt, a hydroxybutanedioic acid salt or a fumaric acid salt.

30. Use of a compound of any of claims 1-21, 26 and 27 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament.

31. Use according to claim 30, wherein the medicament is for treating and/or preventing a proliferation disorder, cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease.

32. Use according to claim 31, wherein the proliferation disorder is selected from the group consisting of sarcoma, epidermoid cancer, fibrosarcoma, cervical cancer, gastric carcinoma, skin cancer, leukemia, lymphoma, lung cancer, non- small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, breast cancer, liver cancer, head and neck cancers, and pancreatic cancer.

33. A combination for treating and/or preventing a proliferation disorder, a cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease in a subject, which combination comprises an effective amount of a compound of any of claims 1-21, 26 and 27, or a pharmaceutically acceptable salt thereof, and an effective amount of a second prophylactic or therapeutic agent for treating and/or preventing a proliferation disorder, a cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease in a subject.

34. The combination of claim 33 for use in a method for treating and/or preventing a proliferation disorder, a cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease in a subject, wherein said combination is for which methods comprises administering in an effective amount to a subject in need thereof an effective amount of the combination of claim 31.